Critical appraisal:Grenabo Bergdahl A, Holmberg E, Moss S, Hugosson J 2013 4

From Cancer Guidelines Wiki

Risk of bias assessment: randomised controlled trial

Was the trial double-blinded?
Outcomes not blinded, substantial side-effects, or not reported.
Was the treatment allocation schedule concealed?
Adequately concealed (e.g. central randomisation, numbered or coded bottles, drugs prepared by pharmacy).
Were all randomised participants included in the analysis?
No exclusions or survival analysis used with all subjects included (>95% follow-up for all groups).
The field below is not considered when calculating the risk of bias rating
How was the allocation schedule generated?
Adequate (e.g. random number table, computer random generator, coin tossing, card shuffling)
Overall risk of bias
High risk of bias Additional comments: Please replace this text and include any additional comments in regards to your quality rating


Jutta's tick icon.png This appraisal has been completed.


Article
Grenabo Bergdahl A, Holmberg E, Moss S, Hugosson J. Incidence of prostate cancer after termination of screening in a population-based randomised screening trial. Eur Urol 2013 Nov;64(5):703-9 Available from: http://www.ncbi.nlm.nih.gov/pubmed/23721957.
Assigned to
User:Suzanne.hughes
Topic area
Guidelines:PSA Testing/PSA Protocol
Clinical question
Form
Form:Quality appraisal rct


Section below only relevant for Cancer Council Project Officer

Edit appraisal assignment